| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
We have performed integrative bulk (whole exome sequencing of tumor and normal paired and whole transcriptome sequencing) and single cell analysis of primary and metastatic non-prostate genitourinary cancer specimens, such as renal and bladder tumors.
- Study Design:
- Case-Control
- Study Type:
- Case-Control
- Tumor vs. Matched-Normal
- Total number of consented subjects: 8
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Single Cell RNA Sequencing Illumina NextSeq 500 N/A N/A Whole Exome Sequencing Illumina HiSeq X N/A N/A Bulk RNA Sequencing Illumina NovaSeq N/A N/A Bulk RNA Sequencing Illumina HiSeq 2500 N/A N/A - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Bladder Neoplasms
- Kidney Neoplasms
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Eliezer M. Van Allen, MD. Dana-Farber Cancer Institute, Boston, MA, USA.
-
Funding Sources
- R37 CA222574. National Institutes of Health, Bethesda, MD, USA.
- R01 CA227388. National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator